Preclinical Testing Techniques: Paving the Way for New Oncology Screening Approaches
Cancers · 07.09.2023 · 15 (18) · 4466
DOI: 10.3390/cancers15184466 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 07.09.2023. Verfasst von Antonia van Rijt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Engineering Program, University of Victoria, Victoria, BC V8P 5C2, Canada. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Prior to clinical trials, preclinical testing of oncology drug candidates is performed by evaluating drug candidates with in vitro and in vivo platforms. For in vivo testing, animal models are used to evaluate the toxicity and efficacy of drug candidates. However, animal models often display poor translational results as many drugs that pass preclinical testing fail when tested with humans, with oncology drugs exhibiting especially poor acceptance rates. The FDA Modernization Act 2.0 promotes alternative preclinical testing techniques, presenting the opportunity to use higher complexity in vitro models as an alternative to in vivo testing, including three-dimensional (3D) cell culture models. Three-dimensional tissue cultures address many of the shortcomings of 2D cultures by more closely replicating the tumour microenvironment through a combination of physiologically relevant drug diffusion, paracrine signalling, cellular phenotype, and vascularization that can better mimic native human tissue. This review will discuss the common forms of 3D cell culture, including cell spheroids, organoids, organs-on-a-chip, and 3D bioprinted tissues. Their advantages and limitations will be presented, aiming to discuss the use of these 3D models to accurately represent human tissue and as an alternative to animal testing. The use of 3D culture platforms for preclinical drug development is expected to accelerate as these platforms continue to improve in complexity, reliability, and translational predictivity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biomedical Engineering Program, University of Victoria, Victoria, BC V8P 5C2, Canada.
- VoxCell BioInnovation Inc., Victoria, BC V8T 5L2, Canada.
Zitieren
APA
van Rijt, A., Stefanek, E., & Valente, K. (2023). Preclinical Testing Techniques: Paving the Way for New Oncology Screening Approaches. Cancers, 15(18), 4466. https://doi.org/10.3390/cancers15184466
Vancouver
van Rijt A, Stefanek E, Valente K. Preclinical Testing Techniques: Paving the Way for New Oncology Screening Approaches. Cancers. 2023;15(18):4466. doi:10.3390/cancers15184466
BibTeX
@article{vanRijt2023,
author = {van Rijt, Antonia and Stefanek, Evan and Valente, Karolina},
title = {Preclinical Testing Techniques: Paving the Way for New Oncology Screening Approaches},
journal = {Cancers},
year = {2023},
volume = {15},
number = {18},
pages = {4466},
doi = {10.3390/cancers15184466}
}
EUVIMED